Other Events

ACA Annual Conference and Exhibition 2015

4th and 5th June 2015, Hilton Brighton Metropole

ACA_2015_270x430.jpgFollowing a hugely successful conference in Birmingham which again was sold out, we are delighted to announce that ACA Annual Conference and Exhibition will be held on the 4th and 5th June 2015 at the Hilton Brighton Metropole.

The theme of this year's programme is Combatting Challenges to Continence across the Age Span which will focus on contemporary continence issues affecting people of all ages and their families and the staff who work with them. 

There will also be an extensive exhibition which will feature over 50 companies offering new innovative products and practical solutions. 

To secure your place at conference please visit the registration website and book today! 

The comprehensive programme has been designed based on previous delegate feedback and will tackle contemporary issues affecting those working within continence care. Programme highlights include: 

  • The Future of Continence Services
  • Urology in Transition
  • Consent Through The Ages
  • Ketamine
  • Post Natal Bowel and Bladder Dysfunction
  • CAUTI Reduction
  • IBS and Diet
  • Bowel Medication
  • Perspective and Managing Long Term Catheter Use
  • Supra-pubic Catheters: A Practical Guide 

To view the full programme and to register please visit the conference website

For more information about the Association for Continence Advice visit: www.aca.uk.com  

 ____________________________________________________________________________________

 

A Practical, Expert-Led MDT Workshop: optimising disease management strategies, individualising therapeutic choices and advancing outcomes in mCRPC

Monday 22 June, 18.00-21.30, Crowne Plaza hotel, Glasgow

This meeting is free to attend

The MDT Workshop aims to deliver a highly practical and interactive session for healthcare professionals involved in the care of men with mCRPC. The workshop programme includes expert presentations and opportunities to discuss themes such as how to practically identify disease progression early in patients receiving ADT, benefits of early treatment with next-line therapy for patients progressing on ADT, and recognising patient and disease characteristics that can help optimise treatment strategies in this setting.

The meeting will be chaired by Balaji Venugopal, Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre in Glasgow, and include International Experts Charles Ryan, Associate Professor of Medicine and Urology, University of California, San Francisco, CA, USA  and Eleni Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas, Houston, TX, USA.

The meeting welcomes clinicians, nurses and pharmacists with an interest in mCRPC and advancing treatment outcomes for patients. 3 CPD credits awarded by BAUS for the meeting and further accreditation has been applied for.

This promotional educational meeting is solely sponsored by Janssen and is free to attend.

Please call 0151 294 3204 to register for this event; or email your name, institution details and contact information, quoting reference # JZR050 to registration@meeting-masters.co.uk. A confirmation email will be sent to you after registration.

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447.

PrescribinginformationforZytiga® (abirateroneacetate) canbefoundat:http://www.janssen-pi.co.uk/zytiga/

Date of preparation: March 2015
Item code: PHGB/ZYT/0315/0011

_________________________________________________________________________________________

A Practical, Expert-Led MDT Workshop: optimising disease management strategies, individualising therapeutic choices and advancing outcomes in mCRPC

Tuesday 23 June, 12.00-15.30, Crowne Plaza Liverpool City Centre

This meeting is free to attend

The MDT Workshop aims to deliver a highly practical and interactive session for healthcare professionals involved in the care of men with mCRPC. The workshop programme includes expert presentations and opportunities to discuss themes such as how to practically identify disease progression early in patients receiving ADT, benefits of early treatment with next-line therapy for patients progressing on ADT, and recognising patient and disease characteristics that can help optimise treatment strategies in this setting.

The meeting will be chaired by Zafar Malik, Consultant Clinical Oncologist at the Clatterbridge Cancer Centre and include International Experts Charles Ryan, Associate Professor of Medicine and Urology, University of California, San Francisco, CA, USA and Eleni Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas, Houston, TX, USA.

The meeting welcomes clinicians, nurses and pharmacists with an interest in mCRPC and advancing treatment outcomes for patients. 3 CPD credits awarded by BAUS for the meeting and further accreditation has been applied for.

This promotional educational meeting is solely sponsored by Janssen and is free to attend.

Please call 0151 294 3204 to register for this event; or email your name, institution details and contact information, quoting reference # JZR050 to registration@meeting-masters.co.uk. A confirmation email will be sent to you after registration.

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447.

PrescribinginformationforZytiga® (abirateroneacetate) canbefoundat:http://www.janssen-pi.co.uk/zytiga/

Date of preparation: March 2015
Item code: PHGB/ZYT/0315/0011

____________________________________________________________________________________________

A Practical, Expert-Led MDT Workshop: optimising disease management strategies, individualising therapeutic choices and advancing outcomes in mCRPC

Tuesday 23 June, 18.00-21.30, Hilton Manchester Airport Hotel

This meeting is free to attend

The MDT Workshop aims to deliver a highly practical and interactive session for healthcare professionals involved in the care of men with mCRPC. The workshop programme includes expert presentations and opportunities to discuss themes such as how to practically identify disease progression early in patients receiving ADT, benefits of early treatment with next-line therapy for patients progressing on ADT, and recognising patient and disease characteristics that can help optimise treatment strategies in this setting.

The meeting will be chaired by James Wylie, Consultant Clinical Oncologist The Christie NHS, Manchester and include International Experts Charles Ryan, Associate Professor of Medicine and Urology, University of California, San Francisco, CA, USA and Eleni Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas, Houston, TX, USA.

The meeting welcomes clinicians, nurses and pharmacists with an interest in mCRPC and advancing treatment outcomes for patients. 3 CPD credits awarded by BAUS for the meeting and further accreditation has been applied for.

This promotional educational meeting is solely sponsored by Janssen and is free to attend.

Please call 0151 294 3204 to register for this event; or email your name, institution details and contact information, quoting reference # JZR050 to registration@meeting-masters.co.uk. A confirmation email will be sent to you after registration.

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447.

PrescribinginformationforZytiga® (abirateroneacetate) canbefoundat:http://www.janssen-pi.co.uk/zytiga/

Date of preparation: March 2015
Item code: PHGB/ZYT/0315/0011

________________________________________________________________________________________

 A Practical, Expert-Led MDT Workshop: optimising disease management strategies, individualising therapeutic choices and advancing outcomes in mCRPC 

Wednesday 24 June, 10.00-13.45, IET Birmingham: Austin Court 

This meeting is free to attend 

The MDT Workshop aims to deliver a highly practical and interactive session for healthcare professionals involved in the care of men with mCRPC. The workshop programme includes expert presentations and opportunities to discuss themes such as how to practically identify disease progression early in patients receiving ADT, benefits of early treatment with next-line therapy for patients progressing on ADT, and recognising patient and disease characteristics that can help optimise treatment strategies in this setting.  

The meeting will be chaired by Nick James, Founding Director of the Warwick Cancer Research Unit and Professor of Clinical Oncology at the Queen Elizabeth Hospital, Birmingham and include International Experts Charles Ryan, Associate Professor of Medicine and Urology, University of California, San Francisco, CA, USA and Eleni Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas, Houston, TX, USA. 

The meeting welcomes clinicians, nurses and pharmacists with an interest in mCRPC and advancing treatment outcomes for patients. 3 CPD credits awarded by BAUS for the meeting and further accreditation has been applied for. 

This promotional educational meeting is solely sponsored by Janssen and is free to attend.  

Please call 0151 294 3204 to register for this event; or email your name, institution details and contact information, quoting reference # JZR050 to registration@meeting-masters.co.uk. A confirmation email will be sent to you after registration. 

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447.  

PrescribinginformationforZytiga® (abirateroneacetate) canbefoundat:http://www.janssen-pi.co.uk/zytiga/ 

Date of preparation: March 2015
Item code: PHGB/ZYT/0315/0011

_________________________________________________________________________________________

A Practical, Expert-Led MDT Workshop: optimising disease management strategies, individualising therapeutic choices and advancing outcomes in mCRPC 

Wednesday 24 June, 18.00-21.30, Miskin Manor, Cardiff 

This meeting is free to attend 

The MDT Workshop aims to deliver a highly practical and interactive session for healthcare professionals involved in the care of men with mCRPC. The workshop programme includes expert presentations and opportunities to discuss themes such as how to practically identify disease progression early in patients receiving ADT, benefits of early treatment with next-line therapy for patients progressing on ADT, and recognising patient and disease characteristics that can help optimise treatment strategies in this setting.  

The meeting will be chaired by John Staffurth, Reader in Oncology at the Institute of Cancer Genetics, Cardiff University and include International Experts Charles Ryan, Associate Professor of Medicine and Urology, University of California, San Francisco, CA, USA and Eleni Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas, Houston, TX, USA. 

The meeting welcomes clinicians, nurses and pharmacists with an interest in mCRPC and advancing treatment outcomes for patients. 3 CPD credits awarded by BAUS for the meeting and further accreditation has been applied for. 

This promotional educational meeting is solely sponsored by Janssen and is free to attend.  

Please call 0151 294 3204 to register for this event; or email your name, institution details and contact information, quoting reference # JZR050 to registration@meeting-masters.co.uk. A confirmation email will be sent to you after registration. 

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447.  

PrescribinginformationforZytiga® (abirateroneacetate) canbefoundat:http://www.janssen-pi.co.uk/zytiga/ 

Date of preparation: March 2015
Item code: PHGB/ZYT/0315/0011

________________________________________________________________________________________

A Practical, Expert-Led MDT Workshop: optimising disease management strategies, individualising therapeutic choices and advancing outcomes in mCRPC

Thursday 25 June, 15.00-18.45, Sandy Park Conference Centre, Exeter

This meeting is free to attend

The MDT Workshop aims to deliver a highly practical and interactive session for healthcare professionals involved in the care of men with mCRPC. The workshop programme includes expert presentations and opportunities to discuss themes such as how to practically identify disease progression early in patients receiving ADT, benefits of early treatment with next-line therapy for patients progressing on ADT, and recognising patient and disease characteristics that can help optimise treatment strategies in this setting.

The meeting will be chaired by Sarah Pascoe, Consultant Clinical Oncologist, Derriford Hospital, Plymouth and include International Experts Charles Ryan, Associate Professor of Medicine and Urology, University of California, San Francisco, CA, USA and Gordon A. Brown, Associate Professor of Urology and Director of the Urology Residency Program at Rowan University-SOM, Stratford, New Jersey, USA.

The meeting welcomes clinicians, nurses and pharmacists with an interest in mCRPC and advancing treatment outcomes for patients. 3 CPD credits awarded by BAUS for the meeting and further accreditation has been applied for.

This promotional educational meeting is solely sponsored by Janssen and is free to attend.

Please call 0151 294 3204 to register for this event; or email your name, institution details and contact information, quoting reference # JZR050 to registration@meeting-masters.co.uk. A confirmation email will be sent to you after registration.

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447.

PrescribinginformationforZytiga® (abirateroneacetate) canbefoundat:http://www.janssen-pi.co.uk/zytiga/

Date of preparation: March 2015
Item code: PHGB/ZYT/0315/0011

 __________________________________________________________________________________

A Practical, Expert-Led MDT Workshop: optimising disease management strategies, individualising therapeutic choices and advancing outcomes in mCRPC

Friday 26 June, 08.30-12.15, Oxford Spires Four Pillars Hotel, Oxford

This meeting is free to attend

The MDT Workshop aims to deliver a highly practical and interactive session for healthcare professionals involved in the care of men with mCRPC. The workshop programme includes expert presentations and opportunities to discuss themes such as how to practically identify disease progression early in patients receiving ADT, benefits of early treatment with next-line therapy for patients progressing on ADT, and recognising patient and disease characteristics that can help optimise treatment strategies in this setting.

The meeting will be chaired by Andrew Protheroe, Consultant Oncologist at the Oxford University Hospitals NHS Trust and include International Experts Charles Ryan, Associate Professor of Medicine and Urology, University of California, San Francisco, CA, USA and Gordon A. Brown, Associate Professor of Urology and Director of the Urology Residency Program at Rowan University-SOM, Stratford, New Jersey, USA.

The meeting welcomes clinicians, nurses and pharmacists with an interest in mCRPC and advancing treatment outcomes for patients. 3 CPD credits awarded by BAUS for the meeting and further accreditation has been applied for.

This promotional educational meeting is solely sponsored by Janssen and is free to attend.

Please call 0151 294 3204 to register for this event; or email your name, institution details and contact information, quoting reference # JZR050 to registration@meeting-masters.co.uk. A confirmation email will be sent to you after registration.

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447.

PrescribinginformationforZytiga® (abirateroneacetate) canbefoundat:http://www.janssen-pi.co.uk/zytiga/

Date of preparation: March 2015
Item code: PHGB/ZYT/0315/0011

__________________________________________________________________________________________

A Practical, Expert-Led MDT Workshop: optimising disease management strategies, individualising therapeutic choices and advancing outcomes in mCRPC

Friday 26 June, 15.00-18.45, Ambassadors Bloomsbury, London

This meeting is free to attend

The MDT Workshop aims to deliver a highly practical and interactive session for healthcare professionals involved in the care of men with mCRPC. The workshop programme includes expert presentations and opportunities to discuss themes such as how to practically identify disease progression early in patients receiving ADT, benefits of early treatment with next-line therapy for patients progressing on ADT, and recognising patient and disease characteristics that can help optimise treatment strategies in this setting.

The meeting will be chaired by Chris Parker, Consultant Clinical Oncologist at Royal Marsden Hospital, Sutton and include International Experts Charles Ryan, Associate Professor of Medicine and Urology, University of California, San Francisco, CA, USA and Gordon A. Brown, Associate Professor of Urology and Director of the Urology Residency Program at Rowan University-SOM, Stratford, New Jersey, USA.

The meeting welcomes clinicians, nurses and pharmacists with an interest in mCRPC and advancing treatment outcomes for patients. 3 CPD credits awarded by BAUS for the meeting and further accreditation has been applied for.

This promotional educational meeting is solely sponsored by Janssen and is free to attend.

Please call 0151 294 3204 to register for this event; or email your name, institution details and contact information, quoting reference # JZR050 to registration@meeting-masters.co.uk. A confirmation email will be sent to you after registration.

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447.

PrescribinginformationforZytiga® (abirateroneacetate) canbefoundat:http://www.janssen-pi.co.uk/zytiga/

Date of preparation: March 2015
Item code: PHGB/ZYT/0315/0011

_________________________________________________________________________________________

Royal Marsden Web Ad2.jpg

 

  __________________________________________________________________________________

For Clinical Nurse Specialists: 
An Update on the Management of Advanced Prostate Cancer

Friday 12th December 2014, 09.45 – 16.15
The Thistle, Marble Arch, Bryanston Street, London W1H 7EH

Provided by:
British Uro-oncology Group (BUG) 
British Association of Urological Nurses (BAUN)

You are invited to register free of charge for this meeting by following the link below – we hope you will be able to join us.

http://www.bug.uk.com/bug-baun2014.php